SEC Filing Summary: Xenomics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Xenomics, Inc. on October 14, 2005 (signed February 13, 2006). The filing addresses a non-reliance on previously issued financial statements following comments from the SEC Staff regarding the Company's Form SB-2. The Company's independent registered public accounting firm, Lazar Levine & Felix LLP, concurred with management's decision.
Key Financial Metrics and Restatements
The filing details specific adjustments made to financial statements rather than reporting standard operational metrics like revenue or cash flow for the current period. The restatements include:
- Fiscal Year Ended January 31, 2005:
- Benefit of $2,145,101 from the reversal of a charge for acquired in-process research and development.
- Expense of $123,063 for stock-based compensation.
- Expense of $74,404 for deferred founders' compensation contributed to capital.
- Six-Month Period Ended July 31, 2005:
- Expense of $453,294 for stock-based compensation.
The filing text does not provide clear values for total revenue, net profit, operating cash flow, margins, debt, or liquidity positions.
Material Changes Versus Prior Period
The primary material change is the restatement of financial results for the fiscal year ended January 31, 2005, and the interim period ended July 31, 2005. The Company amended its Form 10-KSB and Form 10-QSB on October 28, 2005, to reflect these adjustments. The net impact on the fiscal year 2005 results was a significant increase in reported income due to the reversal of the in-process research and development charge, partially offset by new compensation expenses.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the immediate accounting issue. The primary contingency noted is the requirement to restate historical financial data to comply with SEC accounting standards.
Investor Verification Checklist
- Verify the amended Form 10-KSB for the year ended January 31, 2005, and Form 10-QSB for the period ended July 31, 2005, filed on October 28, 2005.
- Confirm the treatment of the $2.1 million reversal of in-process research and development charges.
- Review the stock-based compensation policies and the calculation of the $453,294 expense for the six-month period.
- Assess the impact of these restatements on the Company's historical profitability and compliance status.